Metformin Efficacy and Safety for Gastric Intestinal Metaplasia
Status:
Not yet recruiting
Trial end date:
2023-10-31
Target enrollment:
Participant gender:
Summary
Gastric intestinal metaplasia significantly increases the risk of gastric cancer. Metformin,
a biguanide, which is widely used for treating diabetes mellitus, has recently been suggested
to have a suppressive effect on tumorigenesis and cancer cell growth. The investigators
devised a prospective randomized controlled trial to evaluate the chemopreventive effect of
metformin against gastric intestinal metaplasia and the safety of this drug in non-diabetic
gastric intestinal metaplasia patients.